
    
      This is the open-label extension to the randomized, double-blind, placebo-and active
      controlled SP515 (NCT00244387) trial that assessed the efficacy and safety and tolerability
      of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease that
      were not well-controlled on levodopa
    
  